• Current treatment options for corneal neovascularization inc

  2024-11-06

  

  Current treatment options for corneal neovascularization include topical application of steroids220, 25, 35, 43 or surgical interventions: laser ablation,14, 203, 234, 48 photodynamic therapy (PDT),4, 93 and fine-needle diathermy.221, 238, 240, 261 Targeting proangiogenic molecules with topical or s

• Estudos de biomarcadores mostram que as concentra es

  2024-11-05

  

  Estudos de biomarcadores mostram que as concentrações de proteína amiloide no LCR estão inversamente relacionadas com o grau de doença de Alzheimer. No entanto, quer as placas amiloides quer a diminuição da proteína amiloide podem ser encontradas em idosos sem clínica de disfunção cognitiva, pelo qu

• br Discussion To our knowledge this is the first case

  2024-11-05

  

  Discussion To our knowledge, this is the first case report that demonstrates the presence of a novel T1151K ALK mutation in a patient with disease progression after crizotinib and then ceritinib. As early as 2011, Zhang et al. identified T1151K among other resistance mutations to crizotinib in Ba

• bax inhibitor In this study we designed and synthesized

  2024-11-05

  

  In this study, we designed and synthesized two ALK PROTACs (degraders), 5 (MS4077) and 6 (MS4078), by linking ceritinib and pomalidomide [45] through two different linkers. Using human ALCL and NSCLC cells, we characterized both compounds in a battery of assays to demonstrate their effects on reduci

• A straightforward synthetic pathway was adopted to synthesiz

  2024-11-05

  

  A straightforward synthetic pathway was adopted to synthesize the target compounds as outlined in . The starting chloromethylquinazolinones (–) were synthesized from anthranilic Quinidine in two steps following reported procedures., , , The first step involves chloroacetylation of anthranilic acid

• We stimulated HNEpC cells with LPS found that the

  2024-11-05

  

  We stimulated HNEpC cells with LPS found that the secretion of inflammatory cytokines and the expression of AHR was increased significantly, and miR124 was reduced. It has been found that LPS as a foreign substance can bind to the TLR family of proteins to activate intracellular AHR signaling [[19],

• Phosphodiesterase inhibition increases the intracellular

  2024-11-05

  

  Phosphodiesterase inhibition increases the intracellular levels of cAMP to restore spontaneous contraction (Essayan, 2001, Qi and Kwan, 1996), acting downstream of adenylyl cyclase. Therefore, cardiac arrest induced by decreased intracellular cAMP levels could be reversed by phosphodiesterase inhibi

• Targeting the BCR is the ideal strategy to identify

  2024-11-05

  

  Targeting the BCR is the ideal strategy to identify the antigen reactive B cells. However, there is concern that B cells could be activated when BCR are bound and cross-linked by antigens, a possibility that is obviously negative for the treatment of autoimmune disease. Proby et al. (2000) tried to

• GS-7340 Application of the broad acting

  2024-11-05

  

  Application of the broad-acting 5-HTR antagonist methiothepin (Bard et al., 1996, Hoyer et al., 1994, Peroutka, 1990) converted the TBS-induced response of both thalamocortical and intracortical A1 synapses from LTP to LTD, an effect that was mimicked by the selective 5-HT2R antagonist ketanserin (L

• While the direct effects of ARI lead

  2024-11-05

  

  While the direct effects of 5-ARI lead to a dramatic Moxifloxacin HCl in serum DHT levels, other laboratory values are also affected by 5-ARI use. Serum testosterone elevations are known to occur with both finasteride and dutasteride use, but values will typically remain within the normal laboratory

• NOXA a member of the

  2024-11-05

  

  NOXA, a member of the pro-apoptotic B-cell lymphoma 2 (BCL-2) family, plays a vital role in regulating mitochondrial or inherent apoptotic pathways [7,8]. NOXA binds to MCL-1 with high affinity and interacts with A1 (known as BCL2A1), resulting in BIM release to trigger subsequent apoptosis [9]. In

• Aurora A or B selective

  2024-11-05

  

  Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas

• The analysis of the profile of protein phosphorylation in

  2024-11-05

  

  The analysis of the profile of protein phosphorylation in MMS-treated WAY-600 confirmed that both the ATM and ATR pathways were activated in S-phase blocked cells. Interestingly, phosphorylation of Chk1 was observed 24h after MMS-treatment both in AT- and ATM-inhibited cells, whilst in the absence

• Several mechanisms of Cd induced carcinogenicity have been r

  2024-11-04

  

  Several mechanisms of Cd-induced carcinogenicity have been reported and are comprehensively summarized by Hartwig [32]. As early as 1980, basic science studies supported a role for endocrine disruption of AR by Cd. Donovan et al. [33], using extracts of mouse prostate cytosol, showed Cd to be the mo

• br Introduction Quenchbody Q body immunoassay

  2024-11-04

  

  Introduction Quenchbody (Q-body) immunoassay is a novel biosensing technology that uses the quenching of fluorescence by intrinsic tryptophan (Trp) residues in antibody variable regions when dye(s) are conjugated to an antibody or antibody fragments in appropriate position, and de-quenching while

16838 records 78/1123 page Previous Next First page 上5页 7677787980 下5页 Last page